Therapeutics of Alzheimer's disease: Past, present and future

2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 2012, The Journal of Nutrition, Health & Aging, 16, 795, 10.1007/s12603-012-0393-5 Adlard, 2008, Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta, Neuron, 59, 43, 10.1016/j.neuron.2008.06.018 Adolfsson, 2012, An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta, J. Neurosci., 32, 9677, 10.1523/JNEUROSCI.4742-11.2012 Ahmed, 2012, Modulatory effects of vitamin E, acetyl-L-carnitine and alpha-lipoic acid on new potential biomarkers for Alzheimer's disease in rat model, Exp. Toxicol. Pathol., 64, 549, 10.1016/j.etp.2010.11.012 Aisen, 2011, Tramiprosate in mild-to-moderate Alzheimer's disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study), Arch. Med. Sci., 7, 102, 10.5114/aoms.2011.20612 Aisen, 2003, Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial, JAMA, 289, 2819, 10.1001/jama.289.21.2819 Aisen, 2008, High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial, JAMA, 300, 1774, 10.1001/jama.300.15.1774 Allegri, 2012, Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia, Drugs Today (Barc), 48, 25, 10.1358/dot.2012.48(Suppl.A).1739721 Andrieux, 2006, Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia, Biol. Psychiatry, 60, 1224, 10.1016/j.biopsych.2006.03.048 Anisuzzaman, 2013, Novel contribution of cell surface and intracellular M1-muscarinic acetylcholine receptors to synaptic plasticity in hippocampus, J. Neurochem., 126, 360, 10.1111/jnc.12306 Anton Alvarez, 2011, Cerebrolysin in Alzheimer's disease, Drugs Today (Barc), 47, 487, 10.1358/dot.2011.47.7.1656496 Aracava, 2005, Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons, J. Pharmacol. Exp. Ther., 312, 1195, 10.1124/jpet.104.077172 Arancio, 2004, RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice, EMBO J., 23, 4096, 10.1038/sj.emboj.7600415 Arendash, 2009, Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice, J. Alzheimers Dis., 17, 661, 10.3233/JAD-2009-1087 Atack, 2010, Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA, Pharmacol. Ther., 125, 11, 10.1016/j.pharmthera.2009.09.001 Atamna, 2008, Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways, FASEB J., 22, 703, 10.1096/fj.07-9610com Atri, 2013, Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy, Alzheimers Res. Ther., 5, 6, 10.1186/alzrt160 Atwood, 2003, Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta, Brain Res. Brain Res. Rev., 43, 1, 10.1016/S0165-0173(03)00174-7 Bachurin, 2001, Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer, Ann. N. Y. Acad. Sci., 939, 425, 10.1111/j.1749-6632.2001.tb03654.x Badiola, 2013, The proton-pump inhibitor lansoprazole enhances amyloid beta production, PLoS One, 8, e58837, 10.1371/journal.pone.0058837 Bajda, 2011, Multi-target-directed ligands in Alzheimer's disease treatment, Curr. Med. Chem., 18, 4949, 10.2174/092986711797535245 Bakchine, 2008, Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study, J. Alzheimers Dis., 13, 97, 10.3233/JAD-2008-13110 Banerjee, 2013, Study of the use of antidepressants for depression in dementia: the HTA-SADD trial–a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine, Health Technol. Assess., 17, 1, 10.3310/hta17070 Barron, 2006, Reproductive hormones modulate oxidative stress in Alzheimer's disease, Antioxid. Redox Signal, 8, 2047, 10.1089/ars.2006.8.2047 Baum, 2008, Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease, J. Clin. Psychopharmacol., 28, 110, 10.1097/jcp.0b013e318160862c Beal, 1992, Mechanisms of excitotoxicity in neurologic diseases, FASEB J., 6, 3338, 10.1096/fasebj.6.15.1464368 Beel, 2008, Substrate specificity of gamma-secretase and other intramembrane proteases, Cell Mol. Life Sci., 65, 1311, 10.1007/s00018-008-7462-2 Benowitz, 1983, Cotinine disposition and effects, Clin. Pharmacol. Ther., 34, 604, 10.1038/clpt.1983.222 Berger-Sweeney, 2003, The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers, Neurosci. Biobehav Rev., 27, 401, 10.1016/S0149-7634(03)00070-8 Bilikiewicz, 2004, Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease, J. Alzheimers Dis., 6, 17, 10.3233/JAD-2004-6103 Birks, 2006, Cholinesterase inhibitors for Alzheimer's disease, Cochrane Database Syst. Rev., CD005593 Blalock, 2010, Effects of long-term pioglitazone treatment on peripheral and central markers of aging, PLoS One, 5, e10405, 10.1371/journal.pone.0010405 Blennow, 2012, Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease, Arch. Neurol., 69, 1002, 10.1001/archneurol.2012.90 Bohrmann, 2012, Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta, J. Alzheimers Dis., 28, 49, 10.3233/JAD-2011-110977 Boimel, 2010, Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice, Exp. Neurol., 224, 472, 10.1016/j.expneurol.2010.05.010 Bondy, 1998, Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid, Brain Res., 799, 91, 10.1016/S0006-8993(98)00461-2 Bosel, 2005, Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones, J. Neurochem., 92, 1386, 10.1111/j.1471-4159.2004.02980.x Boutajangout, 2011, Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain, J. Neurochem., 118, 658, 10.1111/j.1471-4159.2011.07337.x Bowman, 1962, Studies on the metabolism of (-)-cotinine in the human, J. Pharmacol. Exp. Ther., 135, 306 Brioni, 2011, Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease, J. Pharmacol. Exp. Ther., 336, 38, 10.1124/jpet.110.166876 Brookmeyer, 2007, Forecasting the global burden of Alzheimer's disease, Alzheimers Dement., 3, 186, 10.1016/j.jalz.2007.04.381 Bruel-Jungerman, 2011, Cholinergic influences on cortical development and adult neurogenesis, Behav. Brain Res., 221, 379, 10.1016/j.bbr.2011.01.021 Brunden, 2010, Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy, J. Neurosci., 30, 13861, 10.1523/JNEUROSCI.3059-10.2010 Buee, 2000, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Brain Res. Rev., 33, 95, 10.1016/S0165-0173(00)00019-9 Buisson, 1998, Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor, Mol. Pharmacol., 53, 555, 10.1124/mol.53.3.555 Burkhardt, 2004, Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4, J. Alzheimers Dis., 6, 221, 10.3233/JAD-2004-6302 Butterfield, 2003, The glutamatergic system and Alzheimer's disease: therapeutic implications, CNS Drugs, 17, 641, 10.2165/00023210-200317090-00004 Buxbaum, 2002, Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients, Front Biosci., 7, a50, 10.2741/buxbaum Cabrol, 2009, Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening, PLoS One, 4, e5274, 10.1371/journal.pone.0005274 Canas, 2009, Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway, J. Neurosci., 29, 14741, 10.1523/JNEUROSCI.3728-09.2009 Capsoni, 2012, Intranasal “painless” human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice, PLoS One, 7, e37555, 10.1371/journal.pone.0037555 Cardinali, 2010, Clinical aspects of melatonin intervention in Alzheimer's disease progression, Curr. Neuropharmacol., 8, 218, 10.2174/157015910792246209 Casadesus, 2006, Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice, Biochim. Biophys. Acta, 1762, 447, 10.1016/j.bbadis.2006.01.008 Cavas, 2006, Effects of selective neuronal nitric oxide synthase inhibition on sleep and wakefulness in the rat, Prog. Neuropsychopharmacol. Biol. Psychiatry, 30, 56, 10.1016/j.pnpbp.2005.06.013 Chai, 2011, Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression, J. Biol. Chem., 286, 34457, 10.1074/jbc.M111.229633 Chalmers, 1991, Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain–a combined in situ hybridisation/in vitro receptor autoradiographic study, Brain Res., 561, 51, 10.1016/0006-8993(91)90748-K Chan, 2008, Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension, Am. J. Alzheimers Dis. Other Demen., 23, 571, 10.1177/1533317508325093 Chang, 2011, Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice, FASEB J., 25, 775, 10.1096/fj.10-167213 Chauhan, 2008, Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease, Biogerontology, 9, 381, 10.1007/s10522-008-9169-z Chazot, 2010, Therapeutic potential of histamine H3 receptor antagonists in dementias, Drug News Perspect., 23, 99, 10.1358/dnp.2010.23.2.1475899 Chen, 2007, RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease, Curr. Mol. Med., 7, 735, 10.2174/156652407783220741 Cheng, 2010, Inhibition of phosphodiesterase-4 reverses memory deficits produced by Abeta25-35 or Abeta1-40 peptide in rats, Psychopharmacology (Berl), 212, 181, 10.1007/s00213-010-1943-3 Chernyak, 2013, Novel penetrating cations for targeting mitochondria, Curr. Pharm. Des., 19, 2795, 10.2174/1381612811319150015 Chien, 2003, Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole, Mol. Pharmacol., 63, 1322, 10.1124/mol.63.6.1322 Chien, 2005, Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1, Eur. J. Neurosci., 21, 1679, 10.1111/j.1460-9568.2005.03993.x Choi, 2013, Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease, J. Neurochem., 124, 59, 10.1111/jnc.12059 Cibickova, 2007, Differential effects of statins and alendronate on cholinesterases in serum and brain of rats, Physiol. Res., 56, 765, 10.33549/physiolres.931121 Cifariello, 2008, 5-HT(7) receptors in the modulation of cognitive processes, Behav. Brain Res., 195, 171, 10.1016/j.bbr.2007.12.012 Claxton, 2013, Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease, J. Alzheimers Dis., 35, 789, 10.3233/JAD-122308 Clerici, 2012, Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study, Neurol. Sci., 33, 23, 10.1007/s10072-011-0618-0 Coban, 2008, Molecular and cellular mechanisms of DNA vaccines, Hum. Vaccin., 4, 453, 10.4161/hv.4.6.6200 Cole, 2012, Manipulating thyroid status alters endoplasmic reticulum calcium homeostasis in rat cerebellum, Indian J. Exp. Biol., 50, 7 Collina, 2013, Sigma receptor modulators: a patent review, Expert Opin. Ther. Pat., 23, 597, 10.1517/13543776.2013.769522 Colton, 2006, NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 103, 12867, 10.1073/pnas.0601075103 Congdon, 2012, Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo, Autophagy, 8, 609, 10.4161/auto.19048 Corbyn, 2013, New set of Alzheimer's trials focus on prevention, The Lancet, 381, 614, 10.1016/S0140-6736(13)60330-X Cordle, 2005, Mechanisms of statin-mediated inhibition of small G-protein function, J. Biol. Chem., 280, 34202, 10.1074/jbc.M505268200 Cordle, 2005, 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses, J. Neurosci., 25, 299, 10.1523/JNEUROSCI.2544-04.2005 Cornelius, 2004, Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population, Neuroepidemiology, 23, 135, 10.1159/000075957 Corrada, 2005, Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging, Alzheimers Dement, 1, 11, 10.1016/j.jalz.2005.06.001 Coyle, 2001, Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease, Biol. Psychiatry, 49, 289, 10.1016/S0006-3223(00)01101-X Daccache, 2011, Oleuropein and derivatives from olives as Tau aggregation inhibitors, Neurochem. Int., 58, 700, 10.1016/j.neuint.2011.02.010 Dall'Igna, 2007, Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice, Exp. Neurol., 203, 241, 10.1016/j.expneurol.2006.08.008 Dantoine, 2006, Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment, Int. J. Clin. Pract., 60, 110, 10.1111/j.1368-5031.2005.00769.x DaSilva, 2009, scyllo-inositol (ELND005) ameliorates amyloid pathology in an aggressive mouse model of Alzheimer's disease, Alzheimer's Demen. the J. Alzheimer's Assoc., 5, P425, 10.1016/j.jalz.2009.04.950 Davtyan, 2013, Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial, J. Neurosci., 33, 4923, 10.1523/JNEUROSCI.4672-12.2013 de la Monte, 2007, Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery, J. Neuropathol. Exp. Neurol., 66, 272, 10.1097/nen.0b013e318040cfa2 Deane, 2012, A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease, J. Clin. Invest., 122, 1377, 10.1172/JCI58642 Dickey, 2007, The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins, J. Clin. Invest., 117, 648, 10.1172/JCI29715 Dinamarca, 2012, Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer's disease, Front Physiol., 3, 464, 10.3389/fphys.2012.00464 Dockens, 2012, A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects, Clin. Pharmacokinet., 51, 681, 10.1007/s40262-012-0005-x Dodel, 2004, Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, 75, 1472, 10.1136/jnnp.2003.033399 Dodel, 2013, Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial, Lancet Neurol., 12, 233, 10.1016/S1474-4422(13)70014-0 Doody, 2008, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study, Lancet, 372, 207, 10.1016/S0140-6736(08)61074-0 Drever, 2011, The cholinergic system and hippocampal plasticity, Behav. Brain Res., 221, 505, 10.1016/j.bbr.2010.11.037 Dumont, 2012, Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice, Hum. Mol. Genet., 21, 5091, 10.1093/hmg/dds355 Dumont, 2009, Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease, J. Neurochem., 109, 502, 10.1111/j.1471-4159.2009.05970.x Dysken, 2013, Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data, Alzheimers Dement, 10.1016/j.jalz.2013.01.014 Echeverria, 2012, Cotinine: a potential new therapeutic agent against Alzheimer's disease, CNS Neurosci. Ther., 18, 517, 10.1111/j.1755-5949.2012.00317.x Echeverria, 2011, Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice, J. Alzheimers Dis., 24, 817, 10.3233/JAD-2011-102136 Egan, 2012, Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD, Curr. Alzheimer Res., 9, 481, 10.2174/156720512800492530 Ekdahl, 2009, Brain inflammation and adult neurogenesis: the dual role of microglia, Neuroscience, 158, 1021, 10.1016/j.neuroscience.2008.06.052 Engel, 2006, Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert, J. Neurochem., 99, 1445, 10.1111/j.1471-4159.2006.04139.x Eriksdotter-Jonhagen, 2012, Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease, Dement Geriatr. Cogn. Disord., 33, 18, 10.1159/000336051 Eriksen, 2003, NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo, J. Clin. Invest., 112, 440, 10.1172/JCI200318162 Eskelinen, 2009, Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study, J. Alzheimers Dis., 16, 85, 10.3233/JAD-2009-0920 Fan, 2009, Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E, Biofactors, 35, 239, 10.1002/biof.37 Farina, 2012, Vitamin E for Alzheimer's dementia and mild cognitive impairment, Cochrane Database Syst. Rev., 11, CD002854 Farrimond, 2012, Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review, BMJ Open, 2, 10.1136/bmjopen-2012-000917 Feldman, 2010, Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe, Neurology, 74, 956, 10.1212/WNL.0b013e3181d6476a Ferri, 2005, Global prevalence of dementia: a Delphi consensus study, Lancet, 366, 2112, 10.1016/S0140-6736(05)67889-0 Fisher, 2008, Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease, Neurotherapeutics, 5, 433, 10.1016/j.nurt.2008.05.002 Fisher, 2012, Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease, J. Neurochem., 120, 22, 10.1111/j.1471-4159.2011.07507.x Fisher, 2002, AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease, J. Mol. Neurosci., 19, 145, 10.1007/s12031-002-0025-3 Fjord-Larsen, 2012, Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer, Gene Ther., 19, 1010, 10.1038/gt.2011.178 Fleisher, 2011, Chronic divalproex sodium use and brain atrophy in Alzheimer disease, Neurology, 77, 1263, 10.1212/WNL.0b013e318230a16c Fonseca, 2010, Cholesterol and statins in Alzheimer's disease: current controversies, Exp. Neurol., 223, 282, 10.1016/j.expneurol.2009.09.013 Fox, 2005, Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease, Neurology, 64, 1563, 10.1212/01.WNL.0000159743.08996.99 Friedhoff, 2001, Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide, Int. J. Neuropsychopharmacol., 4, 127, 10.1017/S1461145701002310 Froestl, 2013, Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes, J. Alzheimers Dis., 33, 547, 10.3233/JAD-2012-121537 Fu, 2010, Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease, Neuropharmacology, 58, 722, 10.1016/j.neuropharm.2009.12.020 Fu, 2007, Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition, J. Neurosci., 27, 4154, 10.1523/JNEUROSCI.4353-06.2007 Fumagalli, 2008, Neurotrophic factors in neurodegenerative disorders: potential for therapy, CNS Drugs, 22, 1005, 10.2165/0023210-200822120-00004 Gahete, 2010, Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients, J. Alzheimers Dis., 20, 465, 10.3233/JAD-2010-1385 Galasko, 2007, Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals, Alzheimer Dis. Assoc. Disord., 21, 292, 10.1097/WAD.0b013e31815d1048 Galasko, 2012, Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures, Arch. Neurol., 69, 836, 10.1001/archneurol.2012.85 Galimberti, 2013, Immunotherapy against amyloid pathology in Alzheimer's disease, J. Neurol. Sci., 10.1016/j.jns.2012.12.013 Garcia, 2001, Going new places using an old MAP: tau, microtubules and human neurodegenerative disease, Curr. Opin. Cell Biol., 13, 41, 10.1016/S0955-0674(00)00172-1 Garcia-Martinez, 2010, Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells, Biochem. Pharmacol., 79, 239, 10.1016/j.bcp.2009.07.028 Gauthier, 2009, Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study, J. Nutr. Health Aging, 13, 550, 10.1007/s12603-009-0106-x Geerts, 2012, Failure analysis of dimebon using mechanistic disease modeling: lessons for clinical development of new Alzheimer's disease therapies, Alzheimer's Demen., 8, P211, 10.1016/j.jalz.2012.05.588 Geldmacher, 2011, A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease, Arch. Neurol., 68, 45, 10.1001/archneurol.2010.229 Ghosh, 2012, Developing beta-secretase inhibitors for treatment of Alzheimer's disease, J. Neurochem., 120, 71, 10.1111/j.1471-4159.2011.07476.x Gilling, 2009, Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors, Neuropharmacology, 56, 866, 10.1016/j.neuropharm.2009.01.012 Gilman, 2005, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology, 64, 1553, 10.1212/01.WNL.0000159740.16984.3C Giommarelli, 2010, The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition, Cell Mol. Life Sci., 67, 995, 10.1007/s00018-009-0233-x Gozes, 2011, NAP (davunetide) provides functional and structural neuroprotection, Curr. Pharm. Des., 17, 1040, 10.2174/138161211795589373 Gozes, 2008, NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42), BMC Neurosci., 9, S3, 10.1186/1471-2202-9-S3-S3 Gravius, 2011, Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity, Behav. Pharmacol., 22, 122, 10.1097/FBP.0b013e328343d804 Gunasingh, 2008, Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism, Life Sci., 83, 96, 10.1016/j.lfs.2008.05.011 Guntert, 2010, Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease, J. Alzheimers Dis., 21, 585, 10.3233/JAD-2010-100279 Gutzmann, 1998, Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study, J. Neural Transm. Suppl., 54, 301, 10.1007/978-3-7091-7508-8_30 Hampel, 2009, Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study, J. Clin. Psychiatry, 70, 922, 10.4088/JCP.08m04606 Hanyu, 2009, Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus, J. Am. Geriatr. Soc., 57, 177, 10.1111/j.1532-5415.2009.02067.x Hayden, 2007, Does NSAID use modify cognitive trajectories in the elderly? the Cache County study, Neurology, 69, 275, 10.1212/01.wnl.0000265223.25679.2a He, 2013, A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease, Horm. Behav., 64, 1, 10.1016/j.yhbeh.2013.04.009 Hellstrom-Lindahl, 2000, Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists, J. Neurochem., 74, 777, 10.1046/j.1471-4159.2000.740777.x Hellweg, 2012, Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD, Int. J. Geriatr. Psychiatry, 27, 651, 10.1002/gps.2766 Hernandez, 2012, alpha7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?, Curr. Drug Targets, 13, 613, 10.2174/138945012800398973 Hickman, 2008, Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice, J. Neurosci., 28, 8354, 10.1523/JNEUROSCI.0616-08.2008 Hiller, 1981, Tl2+ and Ag2+ metal-ion-induced oxidation of methionine in aqueous solution. A pulse radiolysis study, Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 40, 597, 10.1080/09553008114551581 Hirst, 2006, SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models, Eur. J. Pharmacol., 553, 109, 10.1016/j.ejphar.2006.09.049 Ho, 2009, Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration, J. Alzheimers Dis., 16, 59, 10.3233/JAD-2009-0916 Holmes, 2008, Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial, Lancet, 372, 216, 10.1016/S0140-6736(08)61075-2 Hopkins, 2011, ACS chemical neuroscience molecule spotlight on ELND006: another gamma-secretase inhibitor fails in the clinic, ACS Chem. Neurosci., 2, 279, 10.1021/cn2000469 Howard, 2012, Donepezil and memantine for moderate-to-severe Alzheimer's disease, N. Engl. J. Med., 366, 893, 10.1056/NEJMoa1106668 Hsu, 2010, 197 Hu, 2009, GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals, Neurobiol. Dis., 33, 193, 10.1016/j.nbd.2008.10.007 Hung, 2010, Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease, Ageing Res. Rev., 9, 447, 10.1016/j.arr.2010.05.003 Ikonomovic, 2009, Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease, Arch. Neurol., 66, 646, 10.1001/archneurol.2009.46 Imbimbo, 2009, Why did tarenflurbil fail in Alzheimer's disease?, J. Alzheimers Dis., 17, 757, 10.3233/JAD-2009-1092 Imbimbo, 2011, Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option?, Expert Opin. Investig. Drugs, 20, 325, 10.1517/13543784.2011.550572 Imbimbo, 2010, Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?, Front Aging Neurosci., 2 Jacobsen, 2008, Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade, Proc. Natl. Acad. Sci. U. S. A., 105, 8754, 10.1073/pnas.0710823105 Jaffrey, 2001, Protein S-nitrosylation: a physiological signal for neuronal nitric oxide, Nat. Cell Biol., 3, 193, 10.1038/35055104 Jan, 2011, Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species, J. Biol. Chem., 286, 8585, 10.1074/jbc.M110.172411 Janusz, 2009, Ovine colostrum nanopeptide affects amyloid beta aggregation, FEBS Lett., 583, 190, 10.1016/j.febslet.2008.11.053 Janusz, 2010, Colostral proline-rich polypeptides–immunoregulatory properties and prospects of therapeutic use in Alzheimer's disease, Curr. Alzheimer Res., 7, 323, 10.2174/156720510791162377 Javed, 2012, Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type, Neuroscience, 210, 340, 10.1016/j.neuroscience.2012.02.046 Jia, 2013, Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease, Acta Pharmacol. Sin., 34, 976, 10.1038/aps.2013.7 Jinwal, 2009, Chemical manipulation of hsp70 ATPase activity regulates tau stability, J. Neurosci., 29, 12079, 10.1523/JNEUROSCI.3345-09.2009 Johnson, 2012, A possible role for lutein and zeaxanthin in cognitive function in the elderly, Am. J. Clin. Nutr., 96, 1161S, 10.3945/ajcn.112.034611 Jones, 2006, Extracellular redox state: refining the definition of oxidative stress in aging, Rejuvenation Res., 9, 169, 10.1089/rej.2006.9.169 Jones, 2010, Dimebon disappointment, Alzheimers Res. Ther., 2, 25, 10.1186/alzrt49 Jonhagen, 2000, Nerve growth factor treatment in dementia, Alzheimer Dis. Assoc. Disord., 14, S31, 10.1097/00002093-200000001-00006 Joseph, 2003, Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model, Nutr. Neurosci., 6, 153, 10.1080/1028415031000111282 Kanninen, 2008, Nuclear factor erythroid 2-related factor 2 protects against beta amyloid, Mol. Cell Neurosci., 39, 302, 10.1016/j.mcn.2008.07.010 Karanth, 1993, Role of nitric oxide in interleukin 2-induced corticotropin-releasing factor release from incubated hypothalami, Proc. Natl. Acad. Sci. U. S. A., 90, 3383, 10.1073/pnas.90.8.3383 Karuppagounder, 2009, Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease, Neurochem. Int., 54, 111, 10.1016/j.neuint.2008.10.008 Kelsey, 2010, Nutraceutical antioxidants as novel neuroprotective agents, Molecules, 15, 7792, 10.3390/molecules15117792 Kelso, 2001, Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties, J. Biol. Chem., 276, 4588, 10.1074/jbc.M009093200 Khalili, 2010, Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats, Iran Biomed. J., 14, 59 Kihara, 2001, alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity, J. Biol. Chem., 276, 13541, 10.1074/jbc.M008035200 King, 2008, A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory, Trends Pharmacol. Sci., 29, 482, 10.1016/j.tips.2008.07.001 Kivipelto, 2001, Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study, BMJ, 322, 1447, 10.1136/bmj.322.7300.1447 Klugman, 2012, Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors, J. Alzheimers Dis., 30, 467, 10.3233/JAD-2012-120124 Kozikowski, 2009, Searching for disease modifiers-PKC activation and HDAC inhibition – a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress, ChemMedChem, 4, 1095, 10.1002/cmdc.200900045 Kupershmidt, 2012, The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease, Antioxid. Redox Signal, 17, 860, 10.1089/ars.2011.4279 Kwiatkowski, 1988, Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin, J. Cell Biol., 106, 375, 10.1083/jcb.106.2.375 Lacerda, 2005, Nitric oxide pathway is an important modulator of heat loss in rats during exercise, Brain Res. Bull, 67, 110, 10.1016/j.brainresbull.2005.06.002 Ladu, 2000, Lipoproteins in the central nervous system, Ann. N. Y. Acad. Sci., 903, 167, 10.1111/j.1749-6632.2000.tb06365.x Lagostena, 2010, In the adult hippocampus, chronic nerve growth factor deprivation shifts GABAergic signaling from the hyperpolarizing to the depolarizing direction, J. Neurosci., 30, 885, 10.1523/JNEUROSCI.3326-09.2010 Lahiri, 2007, How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the “LEARn” model (latent early-life associated regulation) may explain the triggering of AD, Curr. Alzheimer Res., 4, 219, 10.2174/156720507780362164 Lahiri, 2008, Early-life events may trigger biochemical pathways for Alzheimer's disease: the “LEARn” model, Biogerontology, 9, 375, 10.1007/s10522-008-9162-6 Lahmy, 2013, Blockade of tau hyperphosphorylation and abeta generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma receptor agonist, in a nontransgenic mouse model of Alzheimer's disease, Neuropsychopharmacology, 38, 1706, 10.1038/npp.2013.70 Lannfelt, 2008, Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial, Lancet Neurol., 7, 779, 10.1016/S1474-4422(08)70167-4 Lasagna-Reeves, 2011, Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies, Curr. Alzheimer Res., 8, 659, 10.2174/156720511796717177 Lee, 2010, The role of microglia in amyloid clearance from the AD brain, J. Neural Transm., 117, 949, 10.1007/s00702-010-0433-4 Lee, 2000, Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality, J. Biol. Chem., 275, 16007, 10.1074/jbc.275.21.16007 Lee, 2004, The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice, Neurobiol. Aging, 25, 1315, 10.1016/j.neurobiolaging.2004.01.005 Lee, 2009, The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start?, Adv. Drug Deliv. Rev., 61, 1316, 10.1016/j.addr.2009.07.016 Lee, 2012, Memantine inhibits alpha3beta2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteries, PLoS One, 7, e40326, 10.1371/journal.pone.0040326 Lefevre, 2008, Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients, Clin. Pharmacol. Ther., 83, 106, 10.1038/sj.clpt.6100242 Leszek, 2002, Colostrinin proline-rich polypeptide complex from ovine colostrum–a long-term study of its efficacy in Alzheimer's disease, Med. Sci. Monit., 8, PI93 Leyva, 2010, Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models, Chem. Biol., 17, 1189, 10.1016/j.chembiol.2010.08.014 Li, 2006, Simvastatin enhances learning and memory independent of amyloid load in mice, Ann. Neurol., 60, 729, 10.1002/ana.21053 Lichtenstein, 2010, Secretase-independent and RhoGTPase/PAK/ERK-dependent regulation of cytoskeleton dynamics in astrocytes by NSAIDs and derivatives, J. Alzheimers Dis., 22, 1135, 10.3233/JAD-2010-101332 Lim, 2001, The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse, J. Neurosci., 21, 8370, 10.1523/JNEUROSCI.21-21-08370.2001 Limon, 2011, GABAergic drugs and Alzheimer's disease, Future Med. Chem., 3, 149, 10.4155/fmc.10.291 Lindsay, 2002, Risk factors for Alzheimer's disease: a prospective analysis from the Canadian study of health and aging, Am. J. Epidemiol., 156, 445, 10.1093/aje/kwf074 Lipton, 2004, Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine, Cell Death Differ., 11, 18, 10.1038/sj.cdd.4401344 Liu, 2013, MER5101, a novel Abeta1-15:DT conjugate vaccine, generates a robust anti-abeta antibody response and attenuates abeta pathology and cognitive deficits in APPswe/PS1DeltaE9 transgenic mice, J. Neurosci., 33, 7027, 10.1523/JNEUROSCI.5924-12.2013 Liu, 2004, O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 101, 10804, 10.1073/pnas.0400348101 Liu, 2006, Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance, Neurosci. Lett., 406, 189, 10.1016/j.neulet.2006.07.020 Lloret, 2009, Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental, J. Alzheimers Dis., 17, 143, 10.3233/JAD-2009-1033 Lodge, 2005, Vitamin E bioavailability in humans, J. Plant Physiol., 162, 790, 10.1016/j.jplph.2005.04.012 Long, 2012, Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation, Bioorg. Med. Chem. Lett., 22, 6048, 10.1016/j.bmcl.2012.08.051 Lopez, 2009, Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease, J. Neurol. Neurosurg. Psychiatry, 80, 600, 10.1136/jnnp.2008.158964 Lu, 2006, Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men, Arch. Neurol., 63, 177, 10.1001/archneur.63.2.nct50002 Lue, 2001, Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism, Exp. Neurol., 171, 29, 10.1006/exnr.2001.7732 Luo, 2007, Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies, Proc. Natl. Acad. Sci. U. S. A., 104, 9511, 10.1073/pnas.0701055104 Luo, 2013, Abeta42-Binding peptoids as amyloid aggregation inhibitors and detection ligands, ACS Chem. Neurosci., 4, 952, 10.1021/cn400011f Ma, 2013, Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice, J. Biol. Chem., 288, 4056, 10.1074/jbc.M112.393751 Maccecchini, 2012, Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans, J. Neurol. Neurosurg. Psychiatry, 83, 894, 10.1136/jnnp-2012-302589 Maczurek, 2008, Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease, Adv. Drug Deliv. Rev., 60, 1463, 10.1016/j.addr.2008.04.015 Maelicke, 2010, Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy, J. Mol. Neurosci., 40, 135, 10.1007/s12031-009-9269-5 Maher-Edwards, 2011, SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study, Int. J. Geriatr. Psychiatry, 26, 536, 10.1002/gps.2562 Maher-Edwards, 2010, Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease, Curr. Alzheimer Res., 7, 374, 10.2174/156720510791383831 Manczak, 2010, Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons, J. Alzheimers Dis., 20, S609, 10.3233/JAD-2010-100564 Mannick, 2001, S-Nitrosylation of mitochondrial caspases, J. Cell Biol., 154, 1111, 10.1083/jcb.200104008 Marazziti, 2012, Distribution of serotonin receptor of type 6 (5-HT(6)) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study, Neurochem. Res., 37, 920, 10.1007/s11064-011-0684-y Marcade, 2008, Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing, J. Neurochem., 106, 392, 10.1111/j.1471-4159.2008.05396.x Marr, 2003, Neprilysin gene transfer reduces human amyloid pathology in transgenic mice, J. Neurosci., 23, 1992, 10.1523/JNEUROSCI.23-06-01992.2003 Martel, 1997, Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta, J. Neurochem., 69, 1995, 10.1046/j.1471-4159.1997.69051995.x Martone, 2009, Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease, J. Pharmacol. Exp. Ther., 331, 598, 10.1124/jpet.109.152975 Maskell, 2003, Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors, Br. J. Pharmacol., 140, 1313, 10.1038/sj.bjp.0705559 Massa, 2010, Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents, J. Clin. Invest., 120, 1774, 10.1172/JCI41356 Matsuoka, 2007, Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage, J. Mol. Neurosci., 31, 165, 10.1385/JMN/31:02:165 Matsuoka, 2008, A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease, J. Pharmacol. Exp. Ther., 325, 146, 10.1124/jpet.107.130526 McKoy, 2012, A novel inhibitor of amyloid beta (Abeta) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease, J. Biol. Chem., 287, 38992, 10.1074/jbc.M112.348037 McShane, 2006, Memantine for dementia, Cochrane Database Syst. Rev., CD003154 Medeiros, 2011, Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline, Am. J. Pathol., 179, 980, 10.1016/j.ajpath.2011.04.041 Medhurst, 2009, Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice, Br. J. Pharmacol., 157, 130, 10.1111/j.1476-5381.2008.00075.x Meltzer, 2010, Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis, Neuropsychopharmacology, 35, 881, 10.1038/npp.2009.176 Merla, 2007, The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation, Am. J. Physiol. Heart Circ. Physiol., 293, H1918, 10.1152/ajpheart.00416.2007 Miguel-Hidalgo, 2012, Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid beta1-40, Eur. J. Pharmacol., 692, 38, 10.1016/j.ejphar.2012.07.032 Mohs, 2005, The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials, Genes Brain Behav., 4, 129, 10.1111/j.1601-183X.2004.00112.x Morris, 2006, Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease, J. Alzheimers Dis., 9, 435, 10.3233/JAD-2006-9410 Moss, 1999, Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type, Alzheimer Dis. Assoc. Disord., 13, 20, 10.1097/00002093-199903000-00003 Moss, 2013, A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease, Br. J. Clin. Pharmacol., 75, 1231, 10.1111/bcp.12018 Motawaj, 2011, Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease, J. Pharmacol. Exp. Ther., 336, 479, 10.1124/jpet.110.174458 Motawaj, 2010, The histaminergic system: a target for innovative treatments of cognitive deficits, Therapie, 65, 415, 10.2515/therapie/2010058 Mousavi, 2009, Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro, Neurochem. Int., 54, 237, 10.1016/j.neuint.2008.12.001 Mozayan, 2007, Statins prevent cholinesterase inhibitor blockade of sympathetic alpha7-nAChR-mediated currents in rat superior cervical ganglion neurons, Am. J. Physiol. Heart Circ. Physiol., 293, H1737, 10.1152/ajpheart.00269.2007 Muayqil, 2012, Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias, Dement Geriatr. Cogn. Dis. Extra, 2, 546, 10.1159/000343479 Murphy, 2007, Targeting antioxidants to mitochondria by conjugation to lipophilic cations, Annu. Rev. Pharmacol. Toxicol., 47, 629, 10.1146/annurev.pharmtox.47.120505.105110 Nakaya, 2011, Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors, Behav. Brain Res., 218, 165, 10.1016/j.bbr.2010.11.053 Nalivaeva, 2012, Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?, J. Neurochem., 120, 167, 10.1111/j.1471-4159.2011.07510.x Nathan, 2013, The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation, Curr. Alzheimer Res., 10, 240, 10.2174/1567205011310030003 Necula, 2007, Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization, Biochemistry, 46, 8850, 10.1021/bi700411k Nelson, 2009, Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: the cache county memory, health and aging study, J. Nutr. Health Aging, 13, 899, 10.1007/s12603-009-0249-9 Ni, 2013, Modulation of alpha7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer's disease brain, J. Alzheimers Dis., 33, 841, 10.3233/JAD-2012-121447 Nicolakakis, 2008, Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, J. Neurosci., 28, 9287, 10.1523/JNEUROSCI.3348-08.2008 Nikolaev, 2009, APP binds DR6 to trigger axon pruning and neuron death via distinct caspases, Nature, 457, 981, 10.1038/nature07767 Nitsch, 2000, The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease, Ann. Neurol., 48, 913, 10.1002/1531-8249(200012)48:6<913::AID-ANA12>3.0.CO;2-S Niva, 2013, Has inhibition of Abeta production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of gamma-secretase inhibitor data, Eur. J. Clin. Pharmacol., 69, 1247, 10.1007/s00228-012-1459-3 Noble, 2005, Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo, Proc. Natl. Acad. Sci. U. S. A., 102, 6990, 10.1073/pnas.0500466102 Novelli, 1988, Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced, Brain Res., 451, 205, 10.1016/0006-8993(88)90765-2 Okun, 2010, From anti-allergic to anti-Alzheimer's: molecular pharmacology of Dimebon, Curr. Alzheimer Res., 7, 97, 10.2174/156720510790691100 Olcese, 2009, Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease, J. Pineal Res., 47, 82, 10.1111/j.1600-079X.2009.00692.x Oliveira, 2010, Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits, J. Neurosci., 30, 16419, 10.1523/JNEUROSCI.3317-10.2010 Orgogozo, 1997, Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area, Rev. Neurol. (Paris), 153, 185 Orgogozo, 2003, Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization, Neurology, 61, 46, 10.1212/01.WNL.0000073623.84147.A8 Ostrowitzki, 2012, Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab, Arch. Neurol., 69, 198, 10.1001/archneurol.2011.1538 Othman, 2013, Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers, Br. J. Clin. Pharmacol., 75, 1299, 10.1111/j.1365-2125.2012.04472.x Padala, 2012, The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study, Am. J. Geriatr. Pharmacother., 10, 296, 10.1016/j.amjopharm.2012.08.002 Padala, 2010, Methylphenidate for apathy and functional status in dementia of the Alzheimer type, Am. J. Geriatr. Psychiatry, 18, 371, 10.1097/JGP.0b013e3181cabcf6 Parachikova, 2010, Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease, PLoS One, 5, e14015, 10.1371/journal.pone.0014015 Park, 2011, Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation, Biochem. Biophys. Res. Commun., 408, 602, 10.1016/j.bbrc.2011.04.068 Parker, 1994, Electron transport chain defects in Alzheimer's disease brain, Neurology, 44, 1090, 10.1212/WNL.44.6.1090 Parnetti, 2002, Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors, Neurol. Sci., 23, S95, 10.1007/s100720200086 Parri, 2010, Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences, Curr. Alzheimer Res., 7, 27, 10.2174/156720510790274464 Parsons, 2013, Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease, Neurotox. Res., 10.1007/s12640-013-9398-z Patat, 2009, Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects, Br. J. Clin. Pharmacol., 67, 299, 10.1111/j.1365-2125.2008.03348.x Payao, 1998, Differential chromosome sensitivity to 5-azacytidine in Alzheimer's disease, Gerontology, 44, 267, 10.1159/000022023 Peskind, 2006, Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial, Am. J. Geriatr. Psychiatry, 14, 704, 10.1097/01.JGP.0000224350.82719.83 Petersen, 2005, Vitamin E and donepezil for the treatment of mild cognitive impairment, N. Engl. J. Med., 352, 2379, 10.1056/NEJMoa050151 Pfaffendorf, 1997, The interaction between methylene blue and the cholinergic system, Br. J. Pharmacol., 122, 95, 10.1038/sj.bjp.0701355 Pinto, 2011, Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type, Ageing Res. Rev., 10, 404 Plosker, 2009, Cerebrolysin: a review of its use in dementia, Drugs Aging, 26, 893, 10.2165/11203320-000000000-00000 Porsteinsson, 2008, Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial, Curr. Alzheimer Res., 5, 83, 10.2174/156720508783884576 Price, 2012, Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease, Behav. Pharmacol., 23, 426, 10.1097/FBP.0b013e3283566082 Prickaerts, 2012, EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors, Neuropharmacology, 62, 1099, 10.1016/j.neuropharm.2011.10.024 Puzzo, 2009, Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model, J. Neurosci., 29, 8075, 10.1523/JNEUROSCI.0864-09.2009 Qin, 2009, PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia, Arch. Neurol., 66, 352, 10.1001/archneurol.2008.588 Qu, 2006, Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice, J. Neurol. Sci., 244, 151, 10.1016/j.jns.2006.02.006 Qu, 2004, Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease, Arch. Neurol., 61, 1859, 10.1001/archneur.61.12.1859 Quinn, 2005, Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials, Brain Res., 1037, 209, 10.1016/j.brainres.2005.01.023 Rafii, 2011, A phase II trial of huperzine A in mild to moderate Alzheimer disease, Neurology, 76, 1389, 10.1212/WNL.0b013e318216eb7b Ramirez-Bermudez, 2012, Alzheimer's disease: critical notes on the history of a medical concept, Arch. Med. Res., 43, 595, 10.1016/j.arcmed.2012.11.008 Rammes, 2001, The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner, Neurosci. Lett., 306, 81, 10.1016/S0304-3940(01)01872-9 Rammes, 2008, Pharmacodynamics of memantine: an update. Curr., Neuropharmacol, 6, 55, 10.2174/157015908783769671 Rammes, 2011, Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices, Neuropharmacology, 60, 982, 10.1016/j.neuropharm.2011.01.051 Ramsey, 2007, Expression of Nrf2 in neurodegenerative diseases, J. Neuropathol. Exp. Neurol., 66, 75, 10.1097/nen.0b013e31802d6da9 Reger, 2008, Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults, J. Alzheimers Dis., 13, 323, 10.3233/JAD-2008-13309 Reid, 2011, Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe, Bioorg. Med. Chem. Lett., 21, 2697, 10.1016/j.bmcl.2010.12.015 Reines, 2004, Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study, Neurology, 62, 66, 10.1212/WNL.62.1.66 Relkin, 2009, 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease, Neurobiol. Aging, 30, 1728, 10.1016/j.neurobiolaging.2007.12.021 Revett, 2013, Glutamate system, amyloid ss peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology, J. Psychiatry Neurosci., 38, 6, 10.1503/jpn.110190 Reynolds, 1995, 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases, Br. J. Pharmacol., 114, 993, 10.1111/j.1476-5381.1995.tb13303.x Riccio, 2006, A nitric oxide signaling pathway controls CREB-mediated gene expression in neurons, Mol. Cell, 21, 283, 10.1016/j.molcel.2005.12.006 Riepe, 2007, Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine, Dement Geriatr. Cogn. Disord., 23, 301, 10.1159/000100875 Ringman, 2008, P4-344: oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study, Alzheimer's Demen. The J. Alzheimer's Assoc., 4, T774, 10.1016/j.jalz.2008.05.2414 Rissman, 2007, GABA(A) receptors in aging and Alzheimer's disease, J. Neurochem., 103, 1285, 10.1111/j.1471-4159.2007.04832.x Ritchie, 2003, Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial, Arch. Neurol., 60, 1685, 10.1001/archneur.60.12.1685 Rodriguez, 2012, The serotonergic system in ageing and Alzheimer's disease, Prog. Neurobiol., 99, 15, 10.1016/j.pneurobio.2012.06.010 Rogers, 2000, Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study, Eur. Neuropsychopharmacol., 10, 195, 10.1016/S0924-977X(00)00067-5 Roher, 2013, Bapineuzumab alters abeta composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy, PLoS One, 8, e59735, 10.1371/journal.pone.0059735 Rojo, 2010, Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease, J. Alzheimers Dis., 19, 573, 10.3233/JAD-2010-1262 Rosenmann, 2013, Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies, Curr. Alzheimer Res., 10, 217, 10.2174/1567205011310030001 Rosenmann, 2006, Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein, Arch. Neurol., 63, 1459, 10.1001/archneur.63.10.1459 Ross, 2007, A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat, Neuropharmacology, 53, 638, 10.1016/j.neuropharm.2007.07.015 Sabbagh, 2011, PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease, Alzheimer Dis. Assoc. Disord., 25, 206, 10.1097/WAD.0b013e318204b550 Sagare, 2007, Clearance of amyloid-beta by circulating lipoprotein receptors, Nat. Med., 13, 1029, 10.1038/nm1635 Saito, 2005, Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation, Nat. Med., 11, 434, 10.1038/nm1206 Sala, 2008, HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects, J. Pharmacol. Exp. Ther., 324, 352, 10.1124/jpet.107.128959 Salloway, 2009, A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease, Neurology, 73, 2061, 10.1212/WNL.0b013e3181c67808 Sanchez-Mejia, 2008, Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease, Nat. Neurosci., 11, 1311, 10.1038/nn.2213 Sano, 2011, A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease, Neurology, 77, 556, 10.1212/WNL.0b013e318228bf11 Santa-Maria, 2007, Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau, Mol. Neurodegener., 2, 17, 10.1186/1750-1326-2-17 Sanz-Blasco, 2008, Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs, PLoS One, 3, e2718, 10.1371/journal.pone.0002718 Saumier, 2009, Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study, J. Nutr. Health Aging, 13, 808, 10.1007/s12603-009-0217-4 Sayas, 1999, The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation, J. Biol. Chem., 274, 37046, 10.1074/jbc.274.52.37046 Schaeffer, 2011, Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein, J. Neural Transm., 118, 1273, 10.1007/s00702-011-0619-4 Schaeffer, 2009, Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease, Psychopharmacology (Berl), 202, 37, 10.1007/s00213-008-1351-0 Schenk, 2012, Treatment strategies targeting amyloid beta-protein, Cold Spring Harb. Perspect. Med., 2, a006387, 10.1101/cshperspect.a006387 Schliebs, 2006, The significance of the cholinergic system in the brain during aging and in Alzheimer's disease, J. Neural Transm., 113, 1625, 10.1007/s00702-006-0579-2 Schneider, 2011, Lack of evidence for the efficacy of memantine in mild Alzheimer disease, Arch. Neurol., 68, 991, 10.1001/archneurol.2011.69 Scott, 2011, N-Aryl-substituted 3-([small beta]-D-glucopyranosyloxy)-2-methyl-4(1H)-pyridinones as agents for Alzheimer's therapy, Chem. Sci., 2, 642, 10.1039/C0SC00544D Selenica, 2007, Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation, Br. J. Pharmacol., 152, 959, 10.1038/sj.bjp.0707471 Shaw, 2001, Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development, Proc. Natl. Acad. Sci. U. S. A., 98, 7605, 10.1073/pnas.131152998 Shemesh, 2012, Effect of intranasal insulin on cognitive function: a systematic review, J. Clin. Endocrinol. Metab., 97, 366, 10.1210/jc.2011-1802 Shen, 2011, 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment, Neuropharmacology, 61, 69, 10.1016/j.neuropharm.2011.02.026 Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X Shi, 2010, H2O2 and PAF mediate Abeta1-42-induced Ca2+ dyshomeostasis that is blocked by EGb761, Neurochem. Int., 56, 893, 10.1016/j.neuint.2010.03.016 Shibata, 2000, Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier, J. Clin. Invest., 106, 1489, 10.1172/JCI10498 Shimohama, 1998, Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease, Neuroscience, 82, 999, 10.1016/S0306-4522(97)00342-4 Siedlak, 2009, Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease, Free Radic. Res., 43, 156, 10.1080/10715760802644694 Siemers, 2010, Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease, Clin. Neuropharmacol., 33, 67, 10.1097/WNF.0b013e3181cb577a Skov, 2008, Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome, PLoS One, 3, e2466, 10.1371/journal.pone.0002466 Slotkin, 1990, Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy, Proc. Natl. Acad. Sci. U. S. A., 87, 2452, 10.1073/pnas.87.7.2452 Smith, 2010, Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease, Int. J. Pharm., 389, 207, 10.1016/j.ijpharm.2010.01.012 Snow, 2010, A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease, Mov Disord., 25, 1670, 10.1002/mds.23148 Sperling, 2012, Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis, Lancet Neurol., 11, 241, 10.1016/S1474-4422(12)70015-7 Stone, 2011, Frontiers in Alzheimer's disease therapeutics, Ther. Adv. Chronic Dis., 2, 9, 10.1177/2040622310382817 Storozhevykh, 2010, Neuroprotective effect of KB-R7943 against glutamate excitotoxicity is related to mild mitochondrial depolarization, Neurochem. Res., 35, 323, 10.1007/s11064-009-0058-x Szekely, 2008, NSAID use and dementia risk in the cardiovascular health study: role of APOE and NSAID type, Neurology, 70, 17, 10.1212/01.wnl.0000284596.95156.48 Tariot, 2009, The ADCS valproate neuroprotection trial: primary efficacy and safety results, Alzheimer's Demen. The J. Alzheimer's Assoc., 5, P84, 10.1016/j.jalz.2009.05.216 Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial, JAMA, 291, 317, 10.1001/jama.291.3.317 Tariot, 2011, Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease, Arch. Gen. Psychiatry, 68, 853, 10.1001/archgenpsychiatry.2011.72 Tayeb, 2013, Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?, Expert Opin. Biol. Ther., 13, 1075, 10.1517/14712598.2013.789856 Thal, 2003, Idebenone treatment fails to slow cognitive decline in Alzheimer's disease, Neurology, 61, 1498, 10.1212/01.WNL.0000096376.03678.C1 Toyohara, 2010, alpha7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease, Open Med. Chem. J., 4, 37 Truelsen, 2002, Amount and type of alcohol and risk of dementia: the Copenhagen city heart study, Neurology, 59, 1313, 10.1212/01.WNL.0000031421.50369.E7 Tuszynski, 2005, A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease, Nat. Med., 11, 551, 10.1038/nm1239 Vellas, 2009, Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders, Curr. Alzheimer Res., 6, 144, 10.2174/156720509787602852 Vellas, 2012, Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial, Lancet Neurol., 11, 851, 10.1016/S1474-4422(12)70206-5 Vellas, 2011, EHT0202 in Alzheimer's disease: a 3-Month, randomized, placebo-controlled, double-blind study, Curr. Alzheimer Res., 8, 203, 10.2174/156720511795256053 Vijayapadma, 2012, Protective effect of lutein against benzo(a)pyrene-induced oxidative stress in human erythrocytes, Toxicol. Ind. Health, 10.1177/0748233712457439 Vilaro, 2005, Serotonin 5-HT4 receptors and their mRNAs in rat and guinea pig brain: distribution and effects of neurotoxic lesions, J. Comp. Neurol., 484, 418, 10.1002/cne.20447 Vitek, 2009, APOE genotype-specific differences in the innate immune response, Neurobiol. Aging, 30, 1350, 10.1016/j.neurobiolaging.2007.11.014 Vozzo, 1999, Effect of nitric oxide synthase inhibitors on short-term appetite and food intake in humans, Am. J. Physiol., 276, R1562 Wahlberg, 2012, Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery, J. Neurosurg., 117, 340, 10.3171/2012.2.JNS11714 Wallace, 2013, Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex, Biochem. Pharmacol., 85, 1713, 10.1016/j.bcp.2013.04.001 Walle, 2011, Bioavailability of resveratrol, Ann. N. Y. Acad. Sci., 1215, 9, 10.1111/j.1749-6632.2010.05842.x Wang, 2006, Role of melatonin in Alzheimer-like neurodegeneration, Acta Pharmacol. Sin, 27, 41, 10.1111/j.1745-7254.2006.00260.x Wang, 1997, Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D, Biochem. Biophys. Res. Commun., 234, 320, 10.1006/bbrc.1997.6636 Wang, 2012, Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AbetaPP/PS1 transgenic mouse brain, J. Alzheimers Dis., 29, 549, 10.3233/JAD-2011-111874 Wang, 2009, Impaired balance of mitochondrial fission and fusion in Alzheimer's disease, J. Neurosci., 29, 9090, 10.1523/JNEUROSCI.1357-09.2009 Watkins, 1994, Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease, JAMA, 271, 992, 10.1001/jama.1994.03510370044030 Webster, 2012, An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease, Neuromolecular Med., 14, 119, 10.1007/s12017-012-8176-z Weggen, 2003, Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity, J. Biol. Chem., 278, 31831, 10.1074/jbc.M303592200 Weinstock, 2000, TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease, J. Neural Transm. Suppl., 157 Weksler, 2002, Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals, Exp. Gerontol., 37, 943, 10.1016/S0531-5565(02)00029-3 Wen, 2011, Alternative mitochondrial electron transfer as a novel strategy for neuroprotection, J. Biol. Chem., 286, 16504, 10.1074/jbc.M110.208447 Wilcock, 2008, Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies, J. Clin. Psychiatry, 69, 341, 10.4088/JCP.v69n0302 Winblad, 2012, Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study, Lancet Neurol., 11, 597, 10.1016/S1474-4422(12)70140-0 Winblad, 2007, IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease, Neurology, 69, S14, 10.1212/01.wnl.0000281847.17519.e0 Wischik, 2008, O3-04-07: tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks, Alzheimer's Demen. The J. Alzheimer's Assoc., 4, T167, 10.1016/j.jalz.2008.05.438 Wright, 2006, Tramiprosate, Drugs Today (Barc), 42, 291, 10.1358/dot.2006.42.5.973584 Xiao, 2010, A meta-analysis of mood stabilizers for Alzheimer's disease, J. Huazhong Univ. Sci. Technol. Med. Sci., 30, 652, 10.1007/s11596-010-0559-5 Xu, 2012, Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease, Prog. Neurobiol., 97, 1, 10.1016/j.pneurobio.2012.02.002 Yang, 2005, Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo, J. Biol. Chem., 280, 5892, 10.1074/jbc.M404751200 Yang, 2013, Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes, J. Alzheimers Dis., 33, 329, 10.3233/JAD-2012-121294 Yasojima, 2001, Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain, Brain Res., 919, 115, 10.1016/S0006-8993(01)03008-6 Yoshimura, 2001, Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element ‘decoy’ of nuclear factor-kappaB binding site as a novel molecular strategy, Gene Ther., 8, 1635, 10.1038/sj.gt.3301566 Youdim, 2005, Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders, Trends Pharmacol. Sci., 26, 27, 10.1016/j.tips.2004.11.007 Youdim, 2001, Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate], Cell Mol. Neurobiol., 21, 555, 10.1023/A:1015131516649 Yu, 2013, Antiinflamm. Antiallergy Agents Med. Chem., 12, 117, 10.2174/1871523011312020003 Yu, 2012, Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation, PLoS One, 7, e35277, 10.1371/journal.pone.0035277 Yue, 2007, Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes, Acta Pharmacol. Sin, 28, 1129, 10.1111/j.1745-7254.2007.00618.x Zandi, 2002, Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study, JAMA, 288, 2123, 10.1001/jama.288.17.2123 Zhang, 2005, Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model, Proc. Natl. Acad. Sci. U. S. A., 102, 227, 10.1073/pnas.0406361102 Zhang, 2008, Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase, Cell Mol. Neurobiol., 28, 173, 10.1007/s10571-007-9163-z Zhao, 2012, Hsp90 modulation for the treatment of Alzheimer's disease, Adv. Pharmacol., 64, 1, 10.1016/B978-0-12-394816-8.00001-5 Zhu, 2007, Alzheimer disease, the two-hit hypothesis: an update, Biochim. Biophys. Acta, 1772, 494, 10.1016/j.bbadis.2006.10.014 Zlokovic, 2004, Clearing amyloid through the blood-brain barrier, J. Neurochem., 89, 807, 10.1111/j.1471-4159.2004.02385.x